Clinical Trial

Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial

Study Description

Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial (CONNECT)

The purpose of this study is to measure changes in smoking behavior during and following sampling of an e-cigarette product. E-cigarettes are classified by the US Food and Drug Administration (FDA) as a tobacco product, though they contain no tobacco. Unlike regular cigarettes, which are burned (creating smoke that is inhaled), e-cigarettes include a heating element that vaporizes nicotine. E-cigarettes are likely much safer than conventional cigarettes, but they may not be entirely safe. We are testing the effects of one specific ecigarette (NJoy) on naturalistic changes in smoking behavior. Neither the tobacco industry nor any ecigarette manufacturer provides support of any kind to this study. There is no requirement to quit smoking in this study, nor is there any requirement to use e-cigarettes.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Behavioral - Electronic Cigarette

An e-cigarette and four weeks of e-liquid provided to participants.

Additional Information

Official Study Title

Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial (CONNECT)

Clinical Trial ID

NCT03453385

ParticipAid ID

7axREd